Lysosome activable polymeric vorinostat encapsulating PD-L1KD for a combination of HDACi and immunotherapy

References

• Bernhart E, Stuendl N, Kaltenegger H, et al. (2017). Histone deacetylase inhibitors vorinostat and panobinostat induce G1 cell cycle arrest and apoptosis in multidrug resistant sarcoma cell lines. Oncotarget 8:77254–67.
   PubMedGoogle Scholar
• Bhatnagar V, Gormley NJ, Luo L, et al. (2017). FDA approval summary: daratumumab for treatment of multiple myeloma after one prior therapy. The Oncol 22:1347–53.
   PubMed Web of Science ®Google Scholar
• Campoli M, Ferrone S. (2008). HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance. Oncogene 27:5869–85.
   PubMed Web of Science ®Google Scholar
• Di Pompo G, Salerno M, Rotili D, et al. (2015). Novel histone deacetylase inhibitors induce growth arrest, apoptosis, and differentiation in sarcoma cancer stem cells. J Med Chem 58:4073–9.
   PubMed Web of Science ®Google Scholar
• Dokmanovic M, Clarke C, Marks PA. (2007). Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res 5:981–9.
   PubMed Web of Science ®Google Scholar
• Dolina JS, Sung S-SJ, Novobrantseva TI, et al. (2013). Lipidoid nanoparticles containing PD-L1 siRNA delivered in vivo enter kupffer cells and enhance NK and CD8(+) T Cell-mediated hepatic antiviral immunity. Mol Ther Nucleic Acids 2:e72.
   PubMedGoogle Scholar
• Escors D. (2014). Tumour immunogenicity, antigen presentation and immunological barriers in cancer immunotherapy. New J Sci 2014:1–25.
   Google Scholar
• Fratta E, Coral S, Covre A, et al. (2011). The biology of cancer testis antigens: putative function, regulation and therapeutic potential. Mol Oncol 5:164–82.
   PubMed Web of Science ®Google Scholar
• Fu H, Cheng L, Jin Y, et al. (2019). MAPK inhibitors enhance HDAC inhibitor-induced redifferentiation in papillary thyroid cancer cells harboring BRAF (V600E): an in vitro study. Mol Ther Oncolytics 12:235–45.
   PubMed Web of Science ®Google Scholar
• Ghoneim HE, Zamora AE, Thomas PG, et al. (2016). Cell-intrinsic barriers of T cell-based immunotherapy. Trends Mol Med 22:1000–11.
   PubMed Web of Science ®Google Scholar
• He R, Hou S, Liu C, et al. (2016). Follicular CXCR5- expressing CD8(+) T cells curtail chronic viral infection. Nature 537:412–28.
   PubMed Web of Science ®Google Scholar
• Heninger E, Krueger TE, Lang JM. (2015). Augmenting antitumor immune responses with epigenetic modifying agents. Front Immunol 6:29.
   PubMed Web of Science ®Google Scholar
• Huang M, Zhang J, Yan C, et al. (2019). Small molecule HDAC inhibitors: promising agents for breast cancer treatment. Bioorg Chem 91:103184,
   PubMed Web of Science ®Google Scholar
• Im SJ, Hashimoto M, Gerner MY, et al. (2016). Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. Nature 537:417–21.
   PubMed Web of Science ®Google Scholar
• Kanayama N, Fukushima S, Nishiyama N, et al. (2006). A PEG-based biocompatible block catiomer with high buffering capacity for the construction of polyplex micelles showing efficient gene transfer toward primary cells. ChemMedChem 1:439–44.
   PubMed Web of Science ®Google Scholar
• Kasamon YL, de Claro RA, Wang Y, et al. (2017). FDA approval summary: nivolumab for the treatment of relapsed or progressive classical hodgkin lymphoma. Oncologist 22:585–91.
   PubMed Web of Science ®Google Scholar
• Kazandjian D, Suzman DL, Blumenthal G, et al. (2016). FDA approval summary: nivolumab for the treatment of metastatic non-small cell lung cancer with progression on or after platinum-based chemotherapy. Oncologist 21:634–42.
   PubMed Web of Science ®Google Scholar
• Kim ES. (2017). Avelumab: first global approval. Drugs 77:929–37.
   PubMed Web of Science ®Google Scholar
• Kline J, Gajewski TF. (2010). Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer. Curr Opin Investig Drugs 11:1354–9.
   PubMedGoogle Scholar
• Larkins E, Blumenthal GM, Yuan W, et al. (2017). FDA approval summary: pembrolizumab for the treatment of recurrent or metastatic head and neck squamous cell carcinoma with disease progression on or after platinum-containing chemotherapy. The Oncol 22:873–8.
   PubMed Web of Science ®Google Scholar
• Liu B, Song Y, Liu D. (2017). Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy. J Hematol Oncol 10:174.
   PubMed Web of Science ®Google Scholar
• Maeda T, Towatari M, Kosugi H, et al. (2000). Up-regulation of costimulatory/adhesion molecules by histone deacetylase inhibitors in acute myeloid leukemia cells. Blood 96:3847–56.
   PubMed Web of Science ®Google Scholar
• Martinez-Lostao L, Anel A, Pardo J. (2015). How do cytotoxic lymphocytes kill cancer cells? Clin Cancer Res 21:5047–56.
   PubMed Web of Science ®Google Scholar
• Mizukami Y, Kono K, Daigo Y, et al. (2008). Detection of novel cancer-testis antigen-specific T-cell responses in TIL, regional lymph nodes, and PBL in patients with esophageal squamous cell carcinoma. Cancer Sci 99:1448–54.
   PubMed Web of Science ®Google Scholar
• Murakami N, Riella LV. (2014). Co-inhibitory pathways and their importance in immune regulation. Transplantation 98:3–14.
   PubMed Web of Science ®Google Scholar
• Ning Y-M, Suzman D, Maher VE, et al. (2017). FDA approval summary: atezolizumab for the treatment of patients with progressive advanced urothelial carcinoma after platinum-containing chemotherapy. Oncologist 22:743–9.
   PubMed Web of Science ®Google Scholar
• Pauken KE, Sammons MA, Odorizzi PM, et al. (2016). Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade. Science 354:1160–5.
   PubMed Web of Science ®Google Scholar
• Pauken KE, Sammons MA, Odorizzi PM, et al. (2016). Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade. Science 354:1160–5.
   PubMed Web of Science ®Google Scholar
• Ren X, Wang N, Zhou Y, et al. (2021). An injectable hydrogel using an immunomodulating gelator for amplified tumor immunotherapy by blocking the arginase pathway. Acta Biomater 124:179–90.
   PubMed Web of Science ®Google Scholar
• Ribas A, Hamid O, Daud A, et al. (2016). Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA 315:1600–9.
   PubMed Web of Science ®Google Scholar
• Saito H, Kuroda H, Matsunaga T, et al. (2013). Increased PD-1 expression on CD4+ and CD8+ T cells is involved in immune evasion in gastric cancer. J Surg Oncol 107:517–22.
   PubMed Web of Science ®Google Scholar
• Schmidl C, Delacher M, Huehn J, et al. (2018). Epigenetic mechanisms regulating T-cell responses. J Allergy Clin Immunol 142:728–43.
   PubMed Web of Science ®Google Scholar
• Schreiber RD, Old LJ, Smyth MJ. (2011). Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331:1565–70.
   PubMed Web of Science ®Google Scholar
• Sclafani F. (2017). PD-1 inhibition in metastatic dMMR/MSI-H colorectal cancer. Lancet Oncol 18:1141–2.
   PubMed Web of Science ®Google Scholar
• Sharma P, Allison JP. (2015). Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 161:205–14.
   PubMed Web of Science ®Google Scholar
• Sigalotti L, Fratta E, Coral S, et al. (2014). Epigenetic drugs as immunomodulators for combination therapies in solid tumors. Pharmacol Ther 142:339–50.
   PubMed Web of Science ®Google Scholar
• Vesely MD, Kershaw MH, Schreiber RD, et al. (2011). Natural innate and adaptive immunity to cancer. Annu Rev Immunol 29:235–71.
   PubMed Web of Science ®Google Scholar
• Wang H, Guo Y, Fu M, et al. (2012). Antitumor activity of Chidamide in hepatocellular carcinoma cell lines. Mol Med Rep 5:1503–8.
   PubMed Web of Science ®Google Scholar
• Xia L, Liu Y, Wang Y. (2019). PD-1/PD-L1 blockade therapy in advanced non-small-cell lung cancer: current status and future directions. Oncologist 24:S31–S41.
   PubMed Web of Science ®Google Scholar
• Xia Y, Medeiros LJ, Young KH. (2016). Immune checkpoint blockade: releasing the brake towards hematological malignancies. Blood Rev 30:189–200.
   PubMed Web of Science ®Google Scholar
• Xu JX, Maher VE, Zhang L, et al. (2017). FDA approval summary: nivolumab in advanced renal cell carcinoma after anti-angiogenic therapy and exploratory predictive biomarker analysis. Oncologist 22:311–7.
   PubMed Web of Science ®Google Scholar
• Yamamoto R, Nishikori M, Kitawaki T, et al. (2008). PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. Blood 111:3220–4.
   PubMed Web of Science ®Google Scholar
• Youngblood B, Oestreich KJ, Ha S-J, et al. (2011). Chronic virus infection enforces demethylation of the locus that encodes PD-1 in antigen-specific CD8(+) T cells. Immunity 35:400–12.
   PubMed Web of Science ®Google Scholar
• Youngblood B, Oestreich KJ, Ha S-J, et al. (2011). Chronic virus infection enforces demethylation of the locus that encodes PD-1 in antigen-specific CD8(+) T cells. Immunity 35:400–12.
   PubMed Web of Science ®Google Scholar
• Zhang F, Zhou X, DiSpirito JR, et al. (2014). Epigenetic manipulation restores functions of defective CD8+ T cells from chronic viral infection. Mol Ther 22:1698–706.
   PubMed Web of Science ®Google Scholar
• Zhang F, Zhou X, DiSpirito JR, et al. (2014). Epigenetic manipulation restores functions of defective CD8+ T cells from chronic viral infection. Mol Ther 22:1698–706.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Ren X, Hou Z, et al. (2021). Engineering a photosensitizer nanoplatform for amplified photodynamic immunotherapy via tumor microenvironment modulation. Nanoscale Horiz 6:120–31.
   PubMed Web of Science ®Google Scholar
• Zhou S, Shang Q, Wang N, et al. (2020). Rational design of a minimalist nanoplatform to maximize immunotherapeutic efficacy: four birds with one stone. J Control Release 328:617–30.
   PubMed Web of Science ®Google Scholar